Key Drivers
- Cash conversion
- Thin margins
- Rising leverage
AIAI Summary
HUM is shifting from a simple beat-and-raise name to a proof-of-recovery story, with improving cash generation and portfolio simplification supporting the thesis, but the stock likely won't re-rate until management proves durable margin repair amid medical cost, legal, and Medicare Advantage execution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash conversion
- •Thin margins
- •Rising leverage
HUM's large scale and improved Q2 cash generation support the case, but thin margins, rising leverage, and a richer valuation keep the investment story constrained.
Price Behavior
Key Price Behavior Insights:
- •Rebound above average
- •Support holding
- •Resistance overhead
HUM appears to be in a volatile consolidation, having rebounded above its last month average and holding $381-$385 support, but it remains capped below $394-$404 resistance after an early-August selloff.
Sharp drop from late-July highs into early-August lows, followed by a rebound from the $362 low
Sentiment & News
Key News Insights:
- •EPS beat
- •Margin expansion
- •Legal scrutiny
Humana beat Q2 earnings and is focused on margin recovery, but legal investigations and valuation concerns remain an overhang.
The news is modestly positive for fundamentals, but litigation risk may cap near-term upside until margin execution and guidance traction improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings